Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.

Also called NCT04415164

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04415164
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04415164. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-29 (actual); primary completion 2022-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
Acronym
EXPECT
Condition
Acute Ischemic Stroke
Intervention (Drug)
Xueshuantong lyophilized powder
Intervention (Drug)
Placebo
Intervention (Other)
Guidelines-based standard care
Lead sponsor
Dongzhimen Hospital, Beijing (class: other)
Collaborator
Tianjin University of Traditional Chinese Medicine (class: other)

Record details

Record id
cardio:ct-nct04415164
Content hash
15bd787d250db4e4d9146547a8ce6008b4e2423fe89d21774231b2d9a5574939